Healthcare Professionals

Lupin Neurosciences is committed to working with Healthcare Professionals to develop strategies that stretch beyond access to lifechanging treatment options to optimize patient care in underserved neurological diseases.

NaMuscla® is an antimyotonic agent which is approved by the European Medicines Agency to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders. In randomized controlled trials, NaMuscla® (mexiletine 167 to 500 mg/day 1 ) has been shown to significantly reduce myotonia compared to placebo, restoring skeletal muscle hyperexcitability through its use-dependent, voltage-gated, sodium channel blocking actions which are independent of the cause of channel dysfunction. This resulted in an improvement in patient quality-of-life and other functional outcomes, with gastro-intestinal discomfort reported as the most common adverse event, demonstrating NaMuscla® to be safe and well tolerated. 2,3

The marketing authorization holder for NaMuscla® in EU is Lupin Europe GmbH.

References:
1. Clinical Study Report refers to 200 mg dose which is the amount of mexiletine hydrochloride (corresponding to 166.62mg mexiletine base)
2. NaMuscla® Summary of Product Characteristics, Assistance Publique – Hopitaux de Paris (AP-HP) sponsor of MYOMEX
3. Trivedi et al. 2013

Please select your country of residence for locally approved package leaflets:

EMA approved SmPC
PDF download